Hikal Ltd Falls 7.61%: 3 Key Factors Behind the Steep Weekly Decline

23 March 2026: Sharp Decline to 52-Week Low Amid Market and Sector Weakness

Hikal Ltd’s stock opened the week on a weak note, plunging 7.08% to close at Rs.156.80, marking a fresh 52-week low. The intraday low of Rs.156.25 represented a 7.41% drop from the previous close, underscoring intense selling pressure. This decline was sharper than the Pharmaceuticals & Biotechnology sector’s 3.25% fall and the Sensex’s 3.13% drop, signalling company-specific challenges alongside broader market weakness.

The stock traded below all key moving averages, including the 5-day through 200-day averages, confirming sustained bearish momentum. Technical indicators such as the MACD, RSI, Bollinger Bands, and Know Sure Thing (KST) all pointed to negative trends on weekly and monthly timeframes. The Dow Theory and On-Balance Volume (OBV) assessments also suggested mild bearishness, reinforcing the downtrend.

Fundamentally, Hikal’s operating profits have contracted at a CAGR of -16.94% over five years, with profits declining 66.4% year-on-year. The company’s average ROE of 8.00% and ROCE of 4.44% (HY Dec 2025) indicate subdued profitability and capital efficiency. Elevated leverage, with a debt to EBITDA ratio of 2.51 times, further constrains financial flexibility. These factors contributed to the stock’s underperformance and the downgrade to a Strong Sell rating by MarketsMOJO, reflecting deteriorated fundamentals and technicals.

24-25 March 2026: Short-Lived Recovery Amid Broader Market Rally

Following the steep losses on 23 March, Hikal Ltd rebounded over the next two trading sessions. On 24 March, the stock gained 3.28% to close at Rs.161.95, supported by a broader Sensex rally of 1.95%. The recovery continued on 25 March with a 2.22% gain, closing at Rs.165.55 on increased volume of 60,456 shares, the highest for the week.

This bounce was in line with the sector’s modest recovery but did not signal a reversal of the underlying downtrend. The stock remained below all major moving averages, and technical indicators continued to reflect bearish momentum. The short-term gains were likely driven by market-wide relief rather than company-specific catalysts, as Hikal’s fundamental challenges persisted.

27 March 2026: Renewed Selling Pressure Pushes Stock to New 52-Week Low

On the final trading day of the week, Hikal Ltd’s shares fell sharply again, closing at Rs.155.90, down 5.83% from the previous close. The stock hit an intraday low of Rs.155, marking another 52-week low and underperforming the sector by 4.86%. This decline followed two days of gains, signalling a reversal in short-term momentum.

The broader market also weakened, with the Sensex falling 2.11% amid ongoing bearish sentiment. Hikal’s technical indicators remained negative, with the MACD, Bollinger Bands, and KST all bearish on weekly and monthly charts. The Dow Theory assessment continued to be mildly bearish, and the OBV showed no clear trend, indicating a lack of strong buying interest.

Fundamental metrics remained subdued, with the company’s operating profit CAGR at -16.94% over five years and a debt to EBITDA ratio of 2.51 times. The average ROE of 8.00% and ROCE of 4.44% (HY Dec 2025) further highlighted weak profitability and capital efficiency. Despite trading at a discount with an enterprise value to capital employed ratio of 1.5, the stock’s valuation has not attracted significant buying support.

Daily Price Comparison: Hikal Ltd vs Sensex (23-27 March 2026)

Key Takeaways

1. Persistent Downtrend: Hikal Ltd’s stock has been in a sustained downtrend, hitting multiple 52-week lows this week. The share price fell 7.61% over the week, significantly underperforming the Sensex’s 1.46% decline.

2. Weak Financials and Elevated Leverage: The company’s operating profit CAGR of -16.94% over five years, combined with a 66.4% profit decline year-on-year and a debt to EBITDA ratio of 2.51 times, highlight ongoing financial challenges.

3. Bearish Technical Indicators: Technical signals including MACD, RSI, Bollinger Bands, and KST remain bearish across daily, weekly, and monthly timeframes, reinforcing the negative momentum.

4. Sector and Market Headwinds: The Pharmaceuticals & Biotechnology sector’s weakness and the broader market downturn have compounded selling pressure on Hikal Ltd’s shares.

5. Valuation Discount Not Supporting Price: Despite trading at a discount with an enterprise value to capital employed ratio of 1.5, the stock has not attracted significant buying interest, reflecting investor caution.

Conclusion

Hikal Ltd’s performance over the week ending 27 March 2026 illustrates a company grappling with deteriorating fundamentals, elevated leverage, and persistent bearish technical signals. The stock’s repeated breaches of 52-week lows amid sectoral and market weakness underscore the challenges it faces. While short-term rallies provided brief relief, the overall trend remains negative, with valuation discounts insufficient to reverse the downtrend. Investors should note the combination of weak profitability, high leverage, and adverse technical momentum as key factors shaping the stock’s current trajectory.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today